Clinical Trial Goal
To find out if giving PCV13 and PPSV23 as a vaccination series is safe and works well to prevent pneumococcal disease in adults with CLL
You may be able to join this trial if you:
- Are 18 years old or older
- Have CLL or small lymphocytic lymphoma (SLL)
- Have not gotten a pneumonia vaccine in the last 5 years
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
PCV13 and PPSV23 are vaccines that protect against bacteria that cause pneumococcal disease.
In this trial, you’ll be assigned to 1 of 2 groups based on the treatment you've had for CLL. Both groups will get both vaccines.
In this trial, you’ll be assigned to 1 of 2 groups based on the treatment you've had for CLL. Both groups will get both vaccines.
You’ll get:
- PCV13 – Given as a shot into your muscle
- PPSV23 – Given as a shot into your muscle 2 months after the first vaccine
The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has approved both of the drugs used in this trial. Using them in this combination for people with CLL is new and unproven.
Locations
Huntsman Cancer Institute/University of UtahRECRUITING
Salt Lake City, Utah
Contacts:
- Catherine Cromar, 801-213-5652, catherine.cromar@hci.utah.edu
- Lindsey Gilstrap, 801-213-5652, lindsey.gilstrap@hci.utah.edu
Sponsors
collaborator: National Cancer Institute (NCI), lead: University of Utah
